ACT up +1.69% percent Today $ACT High is at 246.25 and the Low 241.97 with current volume of 567,530.
Recent News posted below.
Actavis Inc ACT other info.
http://investorshangout.com/Actavis-Inc-ACT-53105/
ACT Actavis Inc Recent Headline News
FDA to review Actavis' application for Saphris label expansion
Seeking Alpha - at Seeking Alpha - 55 mins ago
ACT: 244.55 (+3.93)
Actavis Announces FDA Acceptance of sNDA for SAPHRIS® (asenapine) for the Treatment of Bipolar I Disorder in Pediatric Patients
PR Newswire - 2 hrs 40 mins ago
Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' Supplemental New Drug Application (sNDA) for SAPHRIS® (asenapine) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients 10 to 17 years of age. Actavis' sNDA for SAPHRIS has been granted priority review status by the FDA.
ACT: 244.55 (+3.93)
Allergan buyout said nearing
at Investor's Business Daily - Wed Nov 12, 5:51PM CST
Drugmaker Actavis (ACT) is reportedly near a deal to take over Botox maker Allergan (AGN) for at least $60 bil. An agreement could be reached in a matter of weeks, said Bloomberg sources. But in order to avoid a looming hostile takeover bid from...
AGN: 197.43 (+0.92), VRX: 132.92 (+1.83), ACT: 244.55 (+3.93)
New finance chief at Actavis
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:10PM CST
ACT: 244.55 (+3.93)
Actavis, Allergan Reported Near Deal As Valeant Lurks
at Investor's Business Daily - Wed Nov 12, 11:43AM CST
The drug-industry rumor mill got a fresh surge of energy Wednesday on a report that emerging drug giant Actavis (ACT) is nearing a deal to buy Botox maker Allergan (AGN) for at least $60 billion. Reports that the two companies were talking have been...
ZTS: 43.01 (+0.37), AGN: 197.43 (+0.92), VRX: 132.92 (+1.83), ACT: 244.55 (+3.93)
Actavis closing in on Allergan
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:22AM CST
AGN: 197.43 (+0.92), ACT: 244.55 (+3.93)
5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Nov 12, 8:21AM CST
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 23.82 (-0.07), AGN: 197.43 (+0.92), ACT: 244.55 (+3.93), IRWD: 13.76 (+0.01), CBST: 73.23 (+0.92), PFE: 30.60 (+0.18)
Earnings Triple Plays
Bespoke Investment Group - Seeking Alpha - Wed Nov 12, 1:54AM CST
The third quarter earnings season unofficially comes to an end on Thursday when Wal-Mart (NYSE: WMT ) reports earnings before the open. So far this earnings season, more than 2,000 companies have reported their quarterly numbers, and our job here is...
GD: 142.82 (+1.52), ACT: 244.55 (+3.93), CBG: 32.78 (+0.07), HCP: 43.64 (+0.34), BCR: 165.91 (+0.70), PCG: 49.91 (-0.23), AMGN: 161.80 (-0.13), CB: 101.61 (+0.09), SRE: 110.19 (-0.46), PLD: 41.17 (+0.17), HSP: 58.08 (-0.01), TWX: 79.20 (+1.52), KIM: 24.82 (+0.22), CMI: 145.80 (-0.69), ALXN: 194.48 (+0.79), ESS: 201.02 (+0.58), ABBV: 64.44 (+0.68), CAT: 102.37 (-0.62), AAPL: 112.92 (+1.67)
Bill Ackman vs. Allergan, Inc.: Who Will Win the War of Words?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 5:18PM CST
Irvine, Calif.-based Botox maker Allergan is desperately trying to fend off a takeover bid from Valeant Pharmaceuticals , a company with a history of buying rivals and slashing their work forces. In an interesting twist, this deal is being...
AGN: 197.43 (+0.92), VRX: 132.92 (+1.83), ACT: 244.55 (+3.93)
Use Daily, Weekly Charts To See Institutional Buying
at Investor's Business Daily - Tue Nov 11, 4:23PM CST
Plenty of pundits dismiss charts when it comes to helping evaluate a stock's prospects for gains. It's like reading tea leaves, they say, and investors are better off paying attention only to fundamentals and holding for the long term. Cover your...
ACT: 244.55 (+3.93)
Zoetis could be fallback option for Valeant
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:16PM CST
AGN: 197.43 (+0.92), ZTS: 43.01 (+0.37), ACT: 244.55 (+3.93), VRX: 132.92 (+1.83)
Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 23.82 (-0.07), AGN: 197.43 (+0.92), ACT: 244.55 (+3.93), VRX: 132.92 (+1.83), MDT: 69.44 (+0.94), SLXP: 96.01 (+0.46), SNY: 46.87 (+0.31)
Actavis (ACT) Upgraded From Hold to Buy
at The Street - Tue Nov 11, 8:05AM CST
Actavis (ACT) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B-.
ACT: 244.55 (+3.93)
Actavis elects Maria Teresa (Tessa) Hilado as CFO
M2 - Tue Nov 11, 6:46AM CST
Pharmaceutical company Actavis (NYSE:ACT) disclosed on Monday the addition of Maria Teresa (Tessa) Hilado as its chief financial officer.
ACT: 244.55 (+3.93)
Actavis Names Maria Teresa Hilado Chief Financial Officer
PR Newswire - Mon Nov 10, 3:15PM CST
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Maria Teresa (Tessa) Hilado will join the Company, effective December 8, 2014, as Chief Financial Officer.
ACT: 244.55 (+3.93)
Bulls Rule As Volatility Recedes And Investors Position For Holiday Cheer
Scott Martindale - Seeking Alpha - Mon Nov 10, 9:10AM CST
After displaying a classic V-bottom reversal to what turned out to be a quick and anemic attempt by the bears to bring about a real correction, bullish fervor is becoming contagious, especially as the traditionally strong holiday season approaches....
ACT: 244.55 (+3.93), LUV: 39.72 (+0.35), IYZ: 30.80 (+0.25), SPY: 204.70 (+0.74), IDU: 114.03 (-0.31), AMAT: 22.87 (+0.38), JAZZ: 176.00 (+2.47), IYW: 103.76 (+0.87), FDX: 172.02 (+0.22), IYK: 104.70 (+0.58), IYJ: 106.84 (+0.18), XTN: 103.40 (+0.40), IYH: 143.20 (+0.58), LSTR: 76.82 (-0.25), SWKS: 61.23 (+0.24), IYM: 85.36 (+0.42), IYC: 129.98 (+0.32), NXPI: 74.08 (+0.68), SOXX: 87.84 (+0.74), IYF: 88.28 (+0.06), IYE: 48.34 (-0.67), ADM: 50.90 (+0.19), ARRS: 28.60 (+0.19), PJP: 67.45 (+0.25), ALXN: 194.48 (+0.79)
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo
PR Newswire - Mon Nov 10, 7:50AM CST
Today, Analysts Review released its research reports regarding Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), UnitedHealth Group Incorporated (NYSE: UNH), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7807-100free.
ENDP: 68.24 (+0.35), ACT: 244.55 (+3.93), JAZZ: 176.00 (+2.47), UNH: 96.47 (+0.79), CELG: 109.13 (+0.88), CELGZ: 3.15 (+0.02)
Comparing America's 3 Largest Generic Drugs Companies
Joseph Cafariello - at Seeking Alpha - Fri Nov 07, 9:05AM CST
ZTS: 43.01 (+0.37), ACT: 244.58 (+3.96), MYL: 55.14 (+1.34)
Ironwood Pharmaceuticals' Q3 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 12:20PM CST
Ironwood reported a loss of 30 cents per share in the third quarter of 2014, narrower than the year-ago loss of 51 cents
ACT: 244.58 (+3.96), VRX: 132.92 (+1.83), IRWD: 13.76 (+0.01), AUXL: 32.63 (+0.11)
Stocks On Indefinite Tack; Rumors See Actavis Merger
at Investor's Business Daily - Thu Nov 06, 11:05AM CST
Stock indexes moved in an indefinite fashion midday Thursday despite speculation that the European Central Bank is moving closer to quantitative easing. The Nasdaq and the S&P 500 shifted 0.1% up and 0.1% down, unable to find traction in either...
AGN: 197.43 (+0.92), ACT: 244.58 (+3.96), MSFT: 49.29 (+0.51), VZ: 51.11 (+0.29)
Recent News posted below.
Actavis Inc ACT other info.
http://investorshangout.com/Actavis-Inc-ACT-53105/
ACT Actavis Inc Recent Headline News
FDA to review Actavis' application for Saphris label expansion
Seeking Alpha - at Seeking Alpha - 55 mins ago
ACT: 244.55 (+3.93)
Actavis Announces FDA Acceptance of sNDA for SAPHRIS® (asenapine) for the Treatment of Bipolar I Disorder in Pediatric Patients
PR Newswire - 2 hrs 40 mins ago
Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' Supplemental New Drug Application (sNDA) for SAPHRIS® (asenapine) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients 10 to 17 years of age. Actavis' sNDA for SAPHRIS has been granted priority review status by the FDA.
ACT: 244.55 (+3.93)
Allergan buyout said nearing
at Investor's Business Daily - Wed Nov 12, 5:51PM CST
Drugmaker Actavis (ACT) is reportedly near a deal to take over Botox maker Allergan (AGN) for at least $60 bil. An agreement could be reached in a matter of weeks, said Bloomberg sources. But in order to avoid a looming hostile takeover bid from...
AGN: 197.43 (+0.92), VRX: 132.92 (+1.83), ACT: 244.55 (+3.93)
New finance chief at Actavis
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:10PM CST
ACT: 244.55 (+3.93)
Actavis, Allergan Reported Near Deal As Valeant Lurks
at Investor's Business Daily - Wed Nov 12, 11:43AM CST
The drug-industry rumor mill got a fresh surge of energy Wednesday on a report that emerging drug giant Actavis (ACT) is nearing a deal to buy Botox maker Allergan (AGN) for at least $60 billion. Reports that the two companies were talking have been...
ZTS: 43.01 (+0.37), AGN: 197.43 (+0.92), VRX: 132.92 (+1.83), ACT: 244.55 (+3.93)
Actavis closing in on Allergan
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:22AM CST
AGN: 197.43 (+0.92), ACT: 244.55 (+3.93)
5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Nov 12, 8:21AM CST
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 23.82 (-0.07), AGN: 197.43 (+0.92), ACT: 244.55 (+3.93), IRWD: 13.76 (+0.01), CBST: 73.23 (+0.92), PFE: 30.60 (+0.18)
Earnings Triple Plays
Bespoke Investment Group - Seeking Alpha - Wed Nov 12, 1:54AM CST
The third quarter earnings season unofficially comes to an end on Thursday when Wal-Mart (NYSE: WMT ) reports earnings before the open. So far this earnings season, more than 2,000 companies have reported their quarterly numbers, and our job here is...
GD: 142.82 (+1.52), ACT: 244.55 (+3.93), CBG: 32.78 (+0.07), HCP: 43.64 (+0.34), BCR: 165.91 (+0.70), PCG: 49.91 (-0.23), AMGN: 161.80 (-0.13), CB: 101.61 (+0.09), SRE: 110.19 (-0.46), PLD: 41.17 (+0.17), HSP: 58.08 (-0.01), TWX: 79.20 (+1.52), KIM: 24.82 (+0.22), CMI: 145.80 (-0.69), ALXN: 194.48 (+0.79), ESS: 201.02 (+0.58), ABBV: 64.44 (+0.68), CAT: 102.37 (-0.62), AAPL: 112.92 (+1.67)
Bill Ackman vs. Allergan, Inc.: Who Will Win the War of Words?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 5:18PM CST
Irvine, Calif.-based Botox maker Allergan is desperately trying to fend off a takeover bid from Valeant Pharmaceuticals , a company with a history of buying rivals and slashing their work forces. In an interesting twist, this deal is being...
AGN: 197.43 (+0.92), VRX: 132.92 (+1.83), ACT: 244.55 (+3.93)
Use Daily, Weekly Charts To See Institutional Buying
at Investor's Business Daily - Tue Nov 11, 4:23PM CST
Plenty of pundits dismiss charts when it comes to helping evaluate a stock's prospects for gains. It's like reading tea leaves, they say, and investors are better off paying attention only to fundamentals and holding for the long term. Cover your...
ACT: 244.55 (+3.93)
Zoetis could be fallback option for Valeant
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:16PM CST
AGN: 197.43 (+0.92), ZTS: 43.01 (+0.37), ACT: 244.55 (+3.93), VRX: 132.92 (+1.83)
Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 23.82 (-0.07), AGN: 197.43 (+0.92), ACT: 244.55 (+3.93), VRX: 132.92 (+1.83), MDT: 69.44 (+0.94), SLXP: 96.01 (+0.46), SNY: 46.87 (+0.31)
Actavis (ACT) Upgraded From Hold to Buy
at The Street - Tue Nov 11, 8:05AM CST
Actavis (ACT) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B-.
ACT: 244.55 (+3.93)
Actavis elects Maria Teresa (Tessa) Hilado as CFO
M2 - Tue Nov 11, 6:46AM CST
Pharmaceutical company Actavis (NYSE:ACT) disclosed on Monday the addition of Maria Teresa (Tessa) Hilado as its chief financial officer.
ACT: 244.55 (+3.93)
Actavis Names Maria Teresa Hilado Chief Financial Officer
PR Newswire - Mon Nov 10, 3:15PM CST
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Maria Teresa (Tessa) Hilado will join the Company, effective December 8, 2014, as Chief Financial Officer.
ACT: 244.55 (+3.93)
Bulls Rule As Volatility Recedes And Investors Position For Holiday Cheer
Scott Martindale - Seeking Alpha - Mon Nov 10, 9:10AM CST
After displaying a classic V-bottom reversal to what turned out to be a quick and anemic attempt by the bears to bring about a real correction, bullish fervor is becoming contagious, especially as the traditionally strong holiday season approaches....
ACT: 244.55 (+3.93), LUV: 39.72 (+0.35), IYZ: 30.80 (+0.25), SPY: 204.70 (+0.74), IDU: 114.03 (-0.31), AMAT: 22.87 (+0.38), JAZZ: 176.00 (+2.47), IYW: 103.76 (+0.87), FDX: 172.02 (+0.22), IYK: 104.70 (+0.58), IYJ: 106.84 (+0.18), XTN: 103.40 (+0.40), IYH: 143.20 (+0.58), LSTR: 76.82 (-0.25), SWKS: 61.23 (+0.24), IYM: 85.36 (+0.42), IYC: 129.98 (+0.32), NXPI: 74.08 (+0.68), SOXX: 87.84 (+0.74), IYF: 88.28 (+0.06), IYE: 48.34 (-0.67), ADM: 50.90 (+0.19), ARRS: 28.60 (+0.19), PJP: 67.45 (+0.25), ALXN: 194.48 (+0.79)
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo
PR Newswire - Mon Nov 10, 7:50AM CST
Today, Analysts Review released its research reports regarding Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), UnitedHealth Group Incorporated (NYSE: UNH), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7807-100free.
ENDP: 68.24 (+0.35), ACT: 244.55 (+3.93), JAZZ: 176.00 (+2.47), UNH: 96.47 (+0.79), CELG: 109.13 (+0.88), CELGZ: 3.15 (+0.02)
Comparing America's 3 Largest Generic Drugs Companies
Joseph Cafariello - at Seeking Alpha - Fri Nov 07, 9:05AM CST
ZTS: 43.01 (+0.37), ACT: 244.58 (+3.96), MYL: 55.14 (+1.34)
Ironwood Pharmaceuticals' Q3 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 12:20PM CST
Ironwood reported a loss of 30 cents per share in the third quarter of 2014, narrower than the year-ago loss of 51 cents
ACT: 244.58 (+3.96), VRX: 132.92 (+1.83), IRWD: 13.76 (+0.01), AUXL: 32.63 (+0.11)
Stocks On Indefinite Tack; Rumors See Actavis Merger
at Investor's Business Daily - Thu Nov 06, 11:05AM CST
Stock indexes moved in an indefinite fashion midday Thursday despite speculation that the European Central Bank is moving closer to quantitative easing. The Nasdaq and the S&P 500 shifted 0.1% up and 0.1% down, unable to find traction in either...
AGN: 197.43 (+0.92), ACT: 244.58 (+3.96), MSFT: 49.29 (+0.51), VZ: 51.11 (+0.29)
